Aumolertinib and chemotherapy for EGFR L858R lung cancer
Part of Cancer clinical trials.
This trial tests a combination of aumolertinib (a targeted cancer drug) with chemotherapy in patients with advanced lung adenocarcinoma that has a specific genetic mutation called EGFR L858R. The goal is to see if this combination can slow or shrink the cancer better than existing treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic lung adenocarcinoma (stage IIIB, IIIC, or IV) that cannot be treated with surgery or radiation alone
- Your tumor has the EGFR L858R mutation (confirmed by a blood or tissue test)
- You have never received systemic chemotherapy or targeted therapy for advanced lung cancer (prior adjuvant treatments are okay if completed >12 months ago)
- Your overall health status allows you to care for yourself with minimal assistance (ECOG performance status 0–2) and your life expectancy is at least 3 months
- Your blood counts, liver, and kidney function are adequate (measured within 14 days before starting treatment)
- If you can have children, you agree to use highly effective contraception during and after the trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new targeted therapy, Aumolertinib, for adults with a specific type of advanced lung cancer (non-small cell lung cancer) that has certain genetic changes (EGFR mutations). The goal is to see if the drug can shrink or slow the cancer.
This trial tests a combination of two targeted drugs (anlotinib and aumolertinib) as the first treatment for advanced lung cancer with a specific EGFR mutation (L858R). The goal is to see if the combination works better than standard care.
This trial tests a new combination of two targeted drugs (HS-20117 and aumolertinib) in people with advanced EGFR-mutant lung cancer who haven't had treatment yet. The goal is to see if the combination works better than current standard treatments.
This trial tests whether adding a new targeted drug (SHR-A2009) to the standard pill aumolertinib works better than aumolertinib alone for people with advanced lung cancer that has an EGFR mutation. It's for those who haven't had treatment yet.
This Phase 2 study tests two targeted medicines together (aumolertinib plus anlotinib) as first treatment for advanced lung cancer with specific gene changes (EGFR 19del or L858R plus TP53). It aims to see whether the combination is effective and safe when starting treatment.
This study compares two targeted pills, aumolertinib and osimertinib, as the first treatment for people with advanced EGFR-mutant lung cancer. It aims to see which one works better with fewer side effects.
Hear when a new Lung Adenocarcinoma Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.